Tuesday, September 26
Bellinzona Institutes of Science building (Bios+)
- 14:00-16:00 Registration and welcome remarks
Opening lectures
- 16:00-16:40 Keynote speaker: Davide Robbiani
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland
Antibodies against virus and chemokines after COVID-19 - 16:40-17:20 Keynote speaker: Christian Klein
Roche, Zürich, Switzerland
PD-1 cis-targeting of IL2v with the PD1-IL2v immunocytokine to overcome the limitations of aldesleukin and biased IL-2Rbg agonists
Informal, standing dinner (Italian Pizza and drinks) – included with registration fee
Wednesday, September 27
Auditorium Banca Stato
Session 1: Immunotherapy of viral diseases
8:30-9:30 Registration
- 9:30-10:00 Santiago Gonzalez
Institute for Research in Biomedicine (IRB), Bellinzona, Switzerland
The administration of anti-influenza HA antibodies induces an immunosuppression mechanism that impairs the presentation of antigens by lymph node dendritic cells
10:00-10.20 Selected abstracts for one oral presentation
10:20-10:40 Break
- 10:40-11:20 Keynote speaker: Felix Rey
Institute Pasteur, Paris, France
Virus structure and function
11:20-11:40 Selected abstracts for one oral presentation
- 11:40-12:20 Keynote speaker: Eva Harris
University of California (UC), Berkeley, USA
Virology, pathogenesis, immunology, and epidemiology of flaviviruses
12:20-14:00 Lunch
Session 2: Antibody-drug development (Part 1)
- 14:00-14:40 Keynote speaker: Adriano Aguzzi
University of Zürich, Zürich, Switzerland
Antibody therapy for prion disease
14:40-15:00 Selected abstracts for one oral presentation
- 15:00-15:40 Keynote speaker: Dario Neri
Philogen & ETH Zürich, Siena & Zürich, Italy & Switzerland
Antibody-toxin conjugates
15:40-16:00 Selected abstracts for one oral presentation
16:00-16:20 Break
16:20-16:40 Selected abstracts for one oral presentation
- 16:40-17:20 Keynote speaker: Baolin Zhang
Food and Drug Administration (FDA), Silver Spring, USA
Regulatory aspects in antibody-based therapies
Thursday, September 28
Auditorium Banca Stato
Session 3: Immunotherapy of non-viral diseases
- 9:00-9:40 Keynote speaker: Suzan Rooijakkers
University Medical Center (UMC), Utrecht, Netherlands
Immune response against invading bacteria
9:40-10:20 Selected abstracts for one oral presentation
10:00-10:20 Selected abstracts for one oral presentation
10:20-10:40 Break
- 10:40-11:10 Sarah Gerlo
UGent, Gent, Belgium
Targeting cytokine activity: towards applications in infectious disease - 11:10-11:40 Fabio Bagnoli
GSK, Siena, Italy
Immunotherapy against bacterial diseases
11:40-12:00 Selected abstracts for one oral presentation
12:00-12:20 Selected abstracts for one oral presentation
12:20-14:00 Lunch
Session 4: Antibody-drug development (Part 2)
- 14:00-14:40 Keynote speaker: Giuseppe Pantaleo
CHUV, University of Lausanne, Lausanne, Switzerland
Pandemic preparedness antibody development
14:40-15:00 Selected abstracts for one oral presentation
15:00-15:20 Selected abstracts for one oral presentation
- 15:20-15:50 Janice Reichert
The antibody society, USA
Antibody therapeutics for infectious disease: commercial development trends
15:50-16:10 Break
- 16:10-16:40 Arnaud Avril
IRBA, Brétigny-sur-Orge, France
Development of antibodies for biodefense. The example of an antibody neutralizing several species of Orthopoxvirus - 16:40-17:20 Keynote speaker: Davide Corti
Humabs BioMed, a subsidiary of VIR Biotechnology, Bellinzona, Switzerland
Antibodies against infectious diseases
Friday, September 29
Auditorium Banca Stato
Session 5: Host-directed immunotherapies
- 9:30-10:00 Nuria Izquierdo-Useros
IrsiCaixa, Badalona, Spain
When antigen-presenting cells go viral: targeting viral dissemination with anti-Siglec-1 mAbs
10:00-10:20 Selected abstracts for one oral presentation
10:20-10:40 Selected abstracts for one oral presentation
10:40-11:00 Break
- 11:00-11:30 Stylianos Bournazos
The Rockefeller University, NY, USA
Protective and pathogenic activities of the IgG Fc domain
Closing lecture
- 11:30-12:10 Keynote speaker: Federica Sallusto
Institute of Research in Biomedicine (IRB) & ETH Zürich, Bellinzona & Zurich, Switzerland
Antibodies against conserved coronavirus epitopes
12:10-12:30 Conclusion and remarks
